Brookstone Capital Management
GSK icon

Brookstone Capital Management’s GSK GSK Stock Holding History

Brookstone Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.93M Buy
40,002
+2,042
+5% +$104K 0.02% 510
2026
Q2 		$1.99M Sell
37,960
-399
-1% -$21.1K 0.02% 496
2026
Q1 		$2.12M Buy
38,359
+3,427
+10% +$186K 0.02% 455
2025
Q4 		$1.71M Buy
34,932
+464
+1% +$21.6K 0.02% 485
2025
Q3 		$1.49M Buy
34,468
+1,251
+4% +$48.9K 0.02% 510
2025
Q2 		$1.28M Sell
33,217
-373
-1% -$14.3K 0.02% 509
2025
Q1 		$1.3M Buy
33,590
+1,889
+6% +$69.2K 0.02% 493
2024
Q4 		$1.07M Buy
31,701
+5,244
+20% +$189K 0.02% 512
2024
Q3 		$1.08M Buy
26,457
+718
+3% +$29.4K 0.02% 505
2024
Q2 		$1.03M Sell
25,739
-911
-3% -$38.3K 0.02% 496
2024
Q1 		$1.14M Sell
26,650
-1,027
-4% -$42.4K 0.02% 459
2023
Q4 		$1.03M Sell
27,677
-566
-2% -$20.3K 0.02% 451
2023
Q3 		$1000K Buy
28,243
+2,570
+10% +$91.2K 0.02% 423
2023
Q2 		$868K Sell
25,673
-220
-0.8% -$7.89K 0.02% 462
2023
Q1 		$968K Buy
25,893
+5,373
+26% +$188K 0.02% 462
2022
Q4 		$717K Buy
20,520
+1,624
+9% +$54.1K 0.01% 503
2022
Q3 		$574K Sell
18,896
-20,866
-52% -$791K 0.01% 539
2022
Q2 		$2.1M Buy
39,762
+23,697
+148% +$1.31M 0.05% 283
2022
Q1 		$933K Sell
16,065
-20,039
-56% -$1.09M 0.02% 433
2021
Q4 		$1.98M Buy
36,104
+291
+0.8% +$15.1K 0.03% 270
2021
Q3 		$1.74M Buy
35,813
+415
+1% +$20.8K 0.03% 284
2021
Q2 		$1.79M Buy
35,398
+21,724
+159% +$1.04M 0.03% 276
2021
Q1 		$610K Buy
13,674
+6,224
+84% +$283K 0.02% 327
2020
Q4 		$343K Buy
7,450
+1,011
+16% +$46.4K 0.01% 364
2020
Q3 		$303K Buy
+6,439
New +$323K 0.01% 334
2015
Q4 		– Sell
-124
Closed -$6K – 449
2015
Q3 		$6K Sell
124
-1,345
-92% -$70K ﹤0.01% 1338
2015
Q2 		$76K Buy
+1,469
New +$82.7K 0.01% 385

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
JTC Employer Solutions Trustee
JTC Employer Solutions Trustee St Helier, Jersey $1.16B AUM 24.39% 1-Year Est. Return
Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Equity Investment Corp
Equity Investment Corp Atlanta, Georgia $5.3B AUM 8.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Letko, Brosseau & Associates
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.9B AUM 29.83% 1-Year Est. Return
Miller Howard Investments
Miller Howard Investments Kingston, New York $3.72B AUM 18.2% 1-Year Est. Return

Brookstone Capital Management's GSK Position: Q3 2026 in Review

Brookstone Capital Management increased its GSK (GSK) stake by 5.4% in Q3 2026, buying an estimated $104K and bringing the position to 40,002 shares worth $1.93M. The position accounts for 0.02% of the portfolio, ranked #510.

Brookstone Capital Management first reported a position in GSK in Q2 2015 and has held it in 27 quarters since. The position peaked at $2.12M in Q1 2026. 625 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Brookstone Capital Management held 40,002 shares of GSK worth $1.93M as of Q3 2026.
  • Brookstone Capital Management bought 2,042 GSK shares in Q3 2026, an estimated $104K.
  • GSK made up 0.02% of Brookstone Capital Management's portfolio in Q3 2026, its #510 holding.
  • Brookstone Capital Management first reported a position in GSK in Q2 2015 and has held it in 27 quarters since.
  • Brookstone Capital Management's GSK position peaked at $2.12M in Q1 2026.
  • 625 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Brookstone Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.